Allosteric noncompetitive small molecule selective inhibitors of CD45 tyrosine phosphatase suppress T-cell receptor signals and inflammation in vivo

Molecular Pharmacology

Volumn 85, Issue 4, 2014, Pages 553-563

  Perron, Michael D ^a,b   Chowdhury, Shafinaz ^a   Aubry, Isabelle ^b   Purisima, Enrico ^b,d   Tremblay, Michel L ^b,c   Uri Saragovi, H ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; COMPOUND 211; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; BINDING SITE; CELL ACTIVITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; IC 50; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MOLECULAR DOCKING; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS; SPLEEN CELL; T LYMPHOCYTE;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; ANTIGENS, CD45; CELLS, CULTURED; ENZYME ACTIVATION; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-2; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR DOCKING SIMULATION; MUTAGENESIS, SITE-DIRECTED; NAPHTHOQUINONES; PHOSPHORYLATION; PHOSPHOTYROSINE; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84896874570     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.089847     Document Type: Article

References (41)

1. Alexander DR (2000) The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol 12:349-359.
2. Amrein KE, Panholzer B, Flint NA, Bannwarth W, and Burn P (1993) The Src homology 2 domain of the protein-tyrosine kinase p56lck mediates both intermolecular and intramolecular interactions. Proc Natl Acad Sci USA 90:10285-10289. (Pubitemid 23328297)
3. Askenase PW and Van Loverent H (1983) Delayed-type hypersensitivity: activation of mast cells by antigen-specific T-cell factors initiates the cascade of cellular interactions. Immunol Today 4:259-264.
4. Beers SA, Malloy EA, Wu W, Wachter MP, Gunnia U, Cavender D, Harris C, Davis J, Brosius R, and Pellegrino-Gensey JL et al. (1997) Nitroarylhydroxymethylphosphonic acids as inhibitors of CD45. Bioorg Med Chem 5:2203-2211. (Pubitemid 28012608)
5. Bhat S and Purisima EO (2006) Molecular surface generation using a variable-radius solvent probe. Proteins 62:244-261. (Pubitemid 43063022)
6. Blaskovich MA (2009) Drug discovery and protein tyrosine phosphatases. Curr Med Chem 16:2095-2176.
7. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, Merz KM, Jr, Onufriev A, Simmerling C, Wang B, and Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668-1688. (Pubitemid 43076180)
8. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, and Foxwell BM (1997) T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 272:15023-15027. (Pubitemid 27251779)
9. Cui Q, Sulea T, Schrag JD, Munger C, Hung MN, Naïm M, Cygler M, and Purisima EO (2008) Molecular dynamics-solvated interaction energy studies of proteinprotein interactions: the MP1-p14 scaffolding complex. J Mol Biol 379:787-802.
10. D'Oro U, Sakaguchi K, Appella E, and Ashwell JD (1996) Mutational analysis of Lck in CD45-negative T cells: dominant role of tyrosine 394 phosphorylation in kinase activity. Mol Cell Biol 16:4996-5003. (Pubitemid 26272154)
11. Domínguez JM, Fuertes A, Orozco L, Del Monte-Millán M, Delgado E, and Medina M (2012) Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem 287:893-904.
12. Felberg J and Johnson P (1998) Characterization of recombinant CD45 cytoplasmic domain proteins. Evidence for intramolecular and intermolecular interactions. J Biol Chem 273:17839-17845. (Pubitemid 28355129)
13. Glover NR and Tracey AS (2000) The phosphatase domains of LAR, CD45, and PTP1B: structural correlations with peptide-based inhibitors. Biochem Cell Biol 78:39-50. (Pubitemid 30158958)
14. Greer SF, Wang Y, Raman C, and Justement LB (2001) CD45 function is regulated by an acidic 19-amino acid insert in domain II that serves as a binding and phosphoacceptor site for casein kinase 2. J Immunol 166:7208-7218. (Pubitemid 32525594)
15. Hamaguchi T, Takahashi A, Manaka A, Sato M, and Osada H (2001) TU-572, a potent and selective CD45 inhibitor, suppresses IgE-mediated anaphylaxis and murine contact hypersensitivity reactions. Int Arch Allergy Immunol 126:318-324. (Pubitemid 34124198)
16. Hardy JA and Wells JA (2004) Searching for new allosteric sites in enzymes. Curr Opin Struct Biol 14:706-715. (Pubitemid 39592582)
17. Hermiston ML, Xu Z, and Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107-137. (Pubitemid 37174528)
18. Irwin JJ and Shoichet BK (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182. (Pubitemid 40736970)
19. Iwamoto N, Sumi D, Ishii T, Uchida K, Cho AK, Froines JR, and Kumagai Y (2007) Chemical knockdown of protein-tyrosine phosphatase 1B by 1, 2-naphthoquinone through covalent modification causes persistent transactivation of epidermal growth factor receptor. J Biol Chem 282:33396-33404. (Pubitemid 350159512)
20. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, Schwinzer R, Wonigeit K, Lindert RB, Kantarci O, and Schaefer-Klein J et al. (2000) A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 26:495-499.
21. Jakalian A, Jack DB, and Bayly CI (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem 23:1623-1641. (Pubitemid 35330860)
22. Justement LB (1997) The role of CD45 in signal transduction. Adv Immunol 66:1-65. (Pubitemid 27430940)
23. Kashio N, Matsumoto W, Parker S, and Rothstein DM (1998) The second domain of the CD45 protein tyrosine phosphatase is critical for interleukin-2 secretion and substrate recruitment of TCR-zeta in vivo. J Biol Chem 273:33856-33863.
24. Koretzky GA, Picus J, Schultz T, and Weiss A (1991) Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc Natl Acad Sci USA 88:2037-2041. (Pubitemid 21916348)
25. Kung C, Pingel JT, Heikinheimo M, Klemola T, Varkila K, Yoo LI, Vuopala K, Poyhonen M, Uhari M, and Rogers M et al. (2000) Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med 6:343-345. (Pubitemid 30148629)
26. McNeill L, Salmond RJ, Cooper JC, Carret CK, Cassady-Cain RL, Roche-Molina M, Tandon P, Holmes N, and Alexander DR (2007) The differential regulation of Lck kinase phosphorylation sites by CD45 is critical for T cell receptor signaling responses. Immunity 27:425-437. (Pubitemid 47418669)
27. Naïm M, Bhat S, Rankin KN, Dennis S, Chowdhury SF, Siddiqi I, Drabik P, Sulea T, Bayly CI, and Jakalian A et al. (2007) Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 1. Exploring the parameter space. J Chem Inf Model 47:122-133. (Pubitemid 46225568)
28. Nam HJ, Poy F, Saito H, and Frederick CA (2005) Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. J Exp Med 201:441-452. (Pubitemid 40229418)
29. Pingel JT and Thomas ML (1989) Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation. Cell 58:1055-1065. (Pubitemid 19238183)
30. Piver B, Berthou F, Dreano Y, and Lucas D (2001) Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 125:83-91. (Pubitemid 33043758)
31. Purisima EO (1998) Fast summation boundary element method for calculating solvation free energies of macromolecules. J Comput Chem 19:1494-1504. (Pubitemid 128592640)
32. Riddles PW, Blakeley RL, and Zerner B (1983) Reassessment of Ellman's reagent. Methods Enzymol 91:49-60.
33. Streuli M, Hall LR, Saga Y, Schlossman SF, and Saito H (1987) Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med 166:1548-1566. (Pubitemid 18051443)
34. Streuli M, Krueger NX, Thai T, Tang M, and Saito H (1990) Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR. EMBO J 9:2399-2407.
35. Thomas ML and Brown EJ (1999) Positive and negative regulation of Src-family membrane kinases by CD45. Immunol Today 20:406-411. (Pubitemid 29423482)
36. Thomson AW, Mathie IH, and Sewell HF (1987) Cyclophosphamide-induced eosinophilia in the rat: concomitant changes in T-cell subsets, B cells and large granular lymphocytes within lymphoid tissues. Immunology 60:383-388. (Pubitemid 17032874)
37. Trowbridge IS and Thomas ML (1994) CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12:85-116. (Pubitemid 24140410)
38. Ucar G, Gokhan N, Yesilada A, and Bilgin AA (2005) 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci Lett 382:327-331. (Pubitemid 40733646)
39. Urbanek RA, Suchard SJ, Steelman GB, Knappenberger KS, Sygowski LA, Veale CA, and Chapdelaine MJ (2001) Potent reversible inhibitors of the protein tyrosine phosphatase CD45. J Med Chem 44:1777-1793. (Pubitemid 32852184)
40. Wang Y, Guo W, Liang L, and Esselman WJ (1999) Phosphorylation of CD45 by casein kinase 2. Modulation of activity and mutational analysis. J Biol Chem 274:7454-7461.
41. Word JM, Lovell SC, Richardson JS, and Richardson DC (1999) Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol 285:1735-1747. (Pubitemid 29060467)